Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Acelyrin Announces Long-term 32-week Data From The Phase 2B Trial Of Izokibep In Hidradenitis Suppurativa Demonstrating Sustained Responses And Deepening Clinical Benefit

Author: Benzinga Newsdesk | March 11, 2024 08:04am

Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32
Deep and consistent HiSCR responses were observed for placebo patients switching to active treatment
Marked reductions in draining tunnels and skin pain also contributed to clinically meaningful improvements in quality of life
Potential for differentiation was demonstrated with both high clinical responses as well as a favorable safety profile consistent with the IL-17A class and previous izokibep experience

Posted In: SLRN